Under construction – not a live service
Sign in
Taking people in DenmarkNo phase

Testing Urine Vesicles to Detect Lupus Kidney Inflammation

Studies urine vesicles as a non-invasive way to detect lupus kidney disease in adults.

Plain-language title generated from the registry record
Registry title: Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles

Key facts

Where
Kolding and Odense, DenmarkSee the 4 sites

Where in Denmark

  • Kolding HospitalKolding, DenmarkNot yet recruiting
  • Department of NephrologyOdense, DenmarkNot yet recruiting
  • Department of RheumatologyOdense, DenmarkTaking people
  • Univesity of Southern DenmarkOdense, DenmarkNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Kolding Sygehus
Trial code
NCT06642402
Record updated
9 September 2025
Original description
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified and treated based on its histopathological features obtained by invasive kidney biopsy. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers. The primary objective of this prospective study is to investigate the utility of uEVs in LN.Read full original descriptionShow less

Monitoring and Detecting Lupus Nephritis Through Urinary Extracellular Vesicles in Urine

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified and treated based on its histopathological features obtained by invasive kidney biopsy. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers. The primary objective of this prospective study is to investigate the utility of uEVs in LN.

Inclusion: > 18 years old; Fulfilling the 2019 EULAR/ACR classification criteria; Positive autoantibodies, medical history and obejctive examination compatible with SLE; Referred to kidney biopsy; > 18 years old; Fulfilling the 2019 EULAR/ACR classification criteria; Positive autoantibodies, medical history and obejctive examination compatible with SLE; Normal plasma creatinine; Urine albumine/creatinine < 100 mg/g; > 18 years old; No known kidney disease; > 18 years old; Negative autoantibiodies and immunoglobulines; Referred to kidney biopsy.

Exclusion: Significant comorbidity, which is considered to potentially impact the outcome; SLE patients with no sign of kidney disease; Urine albumin-creatinine ratio > 100 mg/g or proteinuria > 100 mg/day; Lack of ability or willingness to provide informed consent; Lack of ability or willingness to provide informed consent; Significant comorbidity, which is considered to potentially impact the outcome; Healthy controls:; Lack of ability or willingness to provide informed consent; Postive autoantibodies; Significant comorbidity, which is considered to potentially impact the outcome; Biopsy control:; Lack of ability or willingness to provide informed consent; Significant comorbidity, which is considered to potentially impact the outcome.

SLE patients with kidney involvement.

ClinicalTrials.gov NCT06642402